Literature DB >> 35996062

Replenishment of myeloid-derived suppressor cells (MDSCs) overrides CR-mediated protection against tumor growth in a murine model of triple-negative breast cancer.

Melissa Carpenter1, Dolly Chowdhury1, Priya Krishna1, Sandy Ng1, Laura C D Pomatto-Watson1, Monica Bodogai2, Oye Bosompra1, Jonathan Kato1, Sarah Wong1, Carlos Reyes-Sepulveda1, Michel Bernier1, Nathan L Price1, Arya Biragyn2, Rafael de Cabo3.   

Abstract

Caloric restriction (CR) is the leading non-pharmacological intervention to delay induced and spontaneous tumors in pre-clinical models. These effects of CR are largely attributed to canonical inhibition of pro-growth pathways. However, our recent data suggest that CR impairs primary tumor growth and cancer progression in the murine 4T1 model of triple negative breast cancer (TNBC), at least in part, through reduced frequency of the myeloid-derived suppressor cells (MDSC). In the present study, we sought to determine whether injection of excess MDSCs could block regression in 4T1 tumor growth and metastatic spread in BALB/cJ female mice undergoing daily CR. Our findings show that MDSC injection impeded CR-mediated protection against tumor growth without increasing lung metastatic burden. Overall, these results reveal that CR can slow cancer progression by affecting immune suppressive cells.Impact statement: Inoculation of MDSCs from donor mice effectively impedes the ability of calorie restriction to protect against primary tumor growth without impacting lung metastatic burden in recipient animals.
© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

Entities:  

Keywords:  Breast Cancer; Caloric Restriction; Fasting Mimicking Diet; Myeloid-derived suppressor cells; metastasis

Year:  2022        PMID: 35996062     DOI: 10.1007/s11357-022-00635-y

Source DB:  PubMed          Journal:  Geroscience        ISSN: 2509-2723            Impact factor:   7.581


  62 in total

1.  Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer.

Authors:  Kenji Gonda; Masahiko Shibata; Tohru Ohtake; Yoshiko Matsumoto; Kazunoshin Tachibana; Noriko Abe; Hitoshi Ohto; Kenichi Sakurai; Seiichi Takenoshita
Journal:  Oncol Lett       Date:  2017-06-02       Impact factor: 2.967

2.  Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.

Authors:  Alessandra Gennari; PierFranco Conte; Riccardo Rosso; Cinzia Orlandini; Paolo Bruzzi
Journal:  Cancer       Date:  2005-10-15       Impact factor: 6.860

3.  Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model.

Authors:  Brittany A Simone; Ajay Palagani; Kimberly Strickland; Kevin Ko; Lianjin Jin; Meng Kieng Lim; Tu D Dan; Mak Sarich; Daniel A Monti; Massimo Cristofanilli; Nicole L Simone
Journal:  Cell Cycle       Date:  2018-08-06       Impact factor: 4.534

4.  Metastatic behavior of breast cancer subtypes.

Authors:  Hagen Kennecke; Rinat Yerushalmi; Ryan Woods; Maggie Chon U Cheang; David Voduc; Caroline H Speers; Torsten O Nielsen; Karen Gelmon
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

5.  Subtypes of breast cancer show preferential site of relapse.

Authors:  Marcel Smid; Yixin Wang; Yi Zhang; Anieta M Sieuwerts; Jack Yu; Jan G M Klijn; John A Foekens; John W M Martens
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

7.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

8.  CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer.

Authors:  Paulino Tallón de Lara; Héctor Castañón; Marijne Vermeer; Nicolás Núñez; Karina Silina; Bettina Sobottka; Joaquín Urdinez; Virginia Cecconi; Hideo Yagita; Farkhondeh Movahedian Attar; Stefanie Hiltbrunner; Isabelle Glarner; Holger Moch; Sònia Tugues; Burkhard Becher; Maries van den Broek
Journal:  Nat Commun       Date:  2021-02-03       Impact factor: 14.919

9.  Predicting response and survival in chemotherapy-treated triple-negative breast cancer.

Authors:  A Prat; A Lluch; J Albanell; W T Barry; C Fan; J I Chacón; J S Parker; L Calvo; A Plazaola; A Arcusa; M A Seguí-Palmer; O Burgues; N Ribelles; A Rodriguez-Lescure; A Guerrero; M Ruiz-Borrego; B Munarriz; J A López; B Adamo; M C U Cheang; Y Li; Z Hu; M L Gulley; M J Vidal; B N Pitcher; M C Liu; M L Citron; M J Ellis; E Mardis; T Vickery; C A Hudis; E P Winer; L A Carey; R Caballero; E Carrasco; M Martín; C M Perou; E Alba
Journal:  Br J Cancer       Date:  2014-08-07       Impact factor: 7.640

Review 10.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.

Authors:  Viktor Fleming; Xiaoying Hu; Rebekka Weber; Vasyl Nagibin; Christopher Groth; Peter Altevogt; Jochen Utikal; Viktor Umansky
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.